RUNDC2A inhibitors represent a relatively specific class of chemical compounds that target the RUN domain-containing protein 2A (RUNDC2A), a protein that plays a crucial role in cellular signaling and regulation of intracellular processes. The RUN domain, an acronym for RPIP8, UNC-14, and NESCA, is a protein structural motif associated with microtubule organization and intracellular trafficking, commonly seen in proteins involved in membrane dynamics and signal transduction pathways. RUNDC2A is primarily characterized by its association with the regulation of cytoskeletal dynamics and protein-protein interactions. These inhibitors are designed to disrupt the normal functional interactions of RUNDC2A, interfering with the signaling mechanisms mediated by this protein. By inhibiting the RUNDC2A, researchers can explore its role in modulating pathways that contribute to a broad range of cellular processes, including cell motility, division, and structural organization.
RUNDC2A inhibitors are typically characterized by their specific binding affinities to the RUN domain, and their molecular structures are designed to interfere with protein conformations required for RUNDC2A activity. These inhibitors have potential utility in studies aiming to understand RUNDC2A's role in various cellular and biochemical pathways. Additionally, these compounds provide valuable insights into the structural and functional consequences of RUN domain disruption, revealing the importance of RUNDC2A in the stabilization of intracellular transport systems and protein interactions. Chemically, these inhibitors may exhibit a wide variety of scaffolds, from small organic molecules to more complex heterocyclic systems, often tailored to ensure selectivity and potency. Advanced computational techniques and structure-activity relationship studies frequently contribute to the design and refinement of RUNDC2A inhibitors, enabling a more nuanced understanding of their molecular interactions within the cell.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Modulates the ubiquitin-proteasome pathway, which can alter RUNDC2A levels and its associated cellular activities. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Inhibits the proteasome, potentially leading to increased RUNDC2A interaction with proteins targeted for degradation. | ||||||